Eqis Capital Management, Inc. Nektar Therapeutics Transaction History

Eqis Capital Management, Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2019 Apr 18, 2019	SELL	$31.58 - $46.35 $250,587 - $367,787	-7,935 Closed	0 $0
Q4 2018 Jan 25, 2019	SELL	$30.43 - $56.65 $182,336 - $339,446	-5,992 Reduced 43.02%	7,935 $261,000
Q3 2018 Oct 17, 2018	BUY	$46.46 - $68.49 $444,482 - $655,243	9,567 Added 219.43%	13,927 $954,000
Q2 2018 Jul 27, 2018	SELL	$46.25 - $104.45 $216,403 - $488,721	-4,679 Reduced 51.76%	4,360 $213,000
Q1 2018 Apr 06, 2018	BUY	$57.4 - $108.44 $274,659 - $518,885	4,785 Added 112.48%	9,039 $960,000
Q4 2017 Jan 25, 2018	BUY	$23.02 - $60.5 $97,927 - $257,367	4,254	4,254 $254,000

145

139M

32.6K

14.1K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $174M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Eqis Capital Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Eqis Capital Management, Inc. with notifications on news.